Presence of mediastinal lymphadenopathy in hospitalized Covid-19 patients in a tertiary care hospital in Pakistan-A cross-sectional study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
03
2022
accepted:
12
05
2023
medline:
29
5
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
The aim of this study was to investigate the presence of mediastinal lymphadenopathy in hospitalized Covid-19 patients in a tertiary care hospital in the metropolitan city of Lahore, Pakistan from September 2020 till July 2021. We retrospectively collected data of Covid-19 patients hospitalized from September 2020 till July 2021. Only those patients who tested PCR positive through a nasopharyngeal swab, were enrolled in the study. Patients' whose data were missing were excluded from this study. Our exclusion criteria included patients who tested negative on Covid-19 PCR, patients with comorbidities that may cause enlarged mediastinal lymphadenopathies such as haemophagocytic lymphohistiocytosis, neoplasia, tuberculosis, sarcoidosis or a systemic disease. The extent of lung involvement in Covid-19 patients was quantified by using a 25-point visual quantitative assessment called the Chest Computed Tomography Score. This score was then correlated with the presence of mediastinal lymphadenopathy. Of the 210 hospitalized patients included in the study, 131 (62.4%) had mediastinal lymphadenopathy. The mean and median Severity Score of Covid-19 patients with mediastinal lymphadenopathy (mean: 17.1, SD:5.7; median: 17, IQR: 13-23) were higher as compared to those without mediastinal lymphadenopathy (mean: 12.3, SD:5.4; median: 12, IQR:9-16). Our study documents a high prevalence of mediastinal lymphadenopathy in hospitalized patients with Covid-19 with the severity score being higher in its presence representing a more severe course of disease.
Sections du résumé
BACKGROUND
The aim of this study was to investigate the presence of mediastinal lymphadenopathy in hospitalized Covid-19 patients in a tertiary care hospital in the metropolitan city of Lahore, Pakistan from September 2020 till July 2021.
METHODS
We retrospectively collected data of Covid-19 patients hospitalized from September 2020 till July 2021. Only those patients who tested PCR positive through a nasopharyngeal swab, were enrolled in the study. Patients' whose data were missing were excluded from this study. Our exclusion criteria included patients who tested negative on Covid-19 PCR, patients with comorbidities that may cause enlarged mediastinal lymphadenopathies such as haemophagocytic lymphohistiocytosis, neoplasia, tuberculosis, sarcoidosis or a systemic disease. The extent of lung involvement in Covid-19 patients was quantified by using a 25-point visual quantitative assessment called the Chest Computed Tomography Score. This score was then correlated with the presence of mediastinal lymphadenopathy.
FINDINGS
Of the 210 hospitalized patients included in the study, 131 (62.4%) had mediastinal lymphadenopathy. The mean and median Severity Score of Covid-19 patients with mediastinal lymphadenopathy (mean: 17.1, SD:5.7; median: 17, IQR: 13-23) were higher as compared to those without mediastinal lymphadenopathy (mean: 12.3, SD:5.4; median: 12, IQR:9-16).
INTERPRETATION
Our study documents a high prevalence of mediastinal lymphadenopathy in hospitalized patients with Covid-19 with the severity score being higher in its presence representing a more severe course of disease.
Identifiants
pubmed: 37228078
doi: 10.1371/journal.pone.0265865
pii: PONE-D-22-06975
pmc: PMC10212126
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265865Informations de copyright
Copyright: © 2023 Bhatti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Vaccine. 2011 Sep 2;29(38):6472-84
pubmed: 21756960
J Med Virol. 2022 Oct;94(10):4869-4877
pubmed: 35754094
World J Clin Cases. 2021 Apr 26;9(12):2703-2710
pubmed: 33969053
Infect Dis Poverty. 2021 Oct 21;10(1):126
pubmed: 34674774
Int J Infect Dis. 2020 Apr;93:192-197
pubmed: 32112966
Front Immunol. 2021 Feb 26;12:631139
pubmed: 33717166
Biomed J. 2020 Aug;43(4):328-333
pubmed: 32387617
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
Pediatr Radiol. 2021 Feb;51(2):222-230
pubmed: 33084963
Lancet Infect Dis. 2020 Nov;20(11):1230-1231
pubmed: 32569623
PLoS One. 2020 Jul 2;15(7):e0235134
pubmed: 32614854
Invest Radiol. 2020 Jun;55(6):327-331
pubmed: 32118615
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Lancet Infect Dis. 2020 Nov;20(11):1230
pubmed: 32330440
Clin Imaging. 2021 Jul;75:119-124
pubmed: 33545439
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
Pol J Radiol. 2020 Jul 17;85:e361-e368
pubmed: 32817769
Acad Radiol. 2021 Jan;28(1):18-27
pubmed: 33067091
Clin Imaging. 2020 Oct;66:35-41
pubmed: 32425338
J Xray Sci Technol. 2020;28(3):391-404
pubmed: 32538893
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326